FTC OKs $1.6B King, Alpharma Deal With Divestiture
The U.S. Federal Trade Commission has allowed King Pharmaceuticals Inc. to complete its approximately $1.6 billion acquisition of rival Alpharma Inc., but it forced the sale of Alpharma's long-acting opioid analgesic...To view the full article, register now.
Already a subscriber? Click here to view full article